Angela Lowenstern1, Shuang Li2, Salim S Virani3, Ann Marie Navar4, Zhuokai Li2, Jennifer G Robinson5, Veronique L Roger6, Anne C Goldberg7, Andrew Koren8, Michael J Louie9, Eric D Peterson4, Tracy Y Wang4. 1. Duke Clinical Research Institute, Durham, NC; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC. Electronic address: angela.sandelin@dm.duke.edu. 2. Duke Clinical Research Institute, Durham, NC. 3. Department of Medicine, Baylor College of Medicine, Houston, TX. 4. Duke Clinical Research Institute, Durham, NC; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC. 5. University of Iowa, Iowa City, IA. 6. Department of Health Sciences Research and Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN. 7. Washington University, St. Louis, MO. 8. Sanofi Pharmaceutical Company, Bridgewater, NJ Washington University, St. Louis, MO. 9. Regeneron Pharmaceuticals, Inc., Tarrytown, NY.
Abstract
Intensive lipid management is critical to reduce cardiovascular (CV) risk for patients with diabetes mellitus (DM). METHODS: We performed an observational study of 7628 patients with (n = 2943) and without DM (n = 4685), enrolled in the Provider Assessment of Lipid Management (PALM) registry and treated at 140 outpatient clinics across the United States in 2015. Patient self-estimated CV risk, patient-perceived statin benefit and risk, observed statin therapy use and dosing were assessed. RESULTS: Patients with DM were more likely to believe that their CV risk was elevated compared with patients without DM (39.1% vs 29.3%, P < .001). Patients with DM were more likely to receive a statin (74.2% vs 63.5%, P < .001) but less likely to be treated with guideline-recommended statin intensity (36.5% vs 46.9%, P < .001), driven by the low proportion (16.5%) of high risk (ASCVD risk ≥7.5%) primary prevention DM patients treated with a high intensity statin. Patients with DM treated with guideline-recommended statin intensity were more likely to believe they were at high CV risk (44.9% vs 38.4%, P = .005) and that statins can reduce this risk (41.1% vs 35.6%, P = .02), compared with patients treated with lower than guideline-recommended statin intensity. Compared with patients with an elevated HgbA1c, patients with well-controlled DM were no more likely to be on a statin (77.9% vs 79.3%, P = .43). CONCLUSIONS: In this nationwide study, the majority of patients with DM were treated with lower than guideline-recommended statin intensity. Patient education and engagement may help providers improve lipid therapy for these high-risk patients.
Intensive lipid management is critical to reduce cardiovascular (CV) risk for patients with diabetes mellitus (DM). METHODS: We performed an observational study of 7628 patients with (n = 2943) and without DM (n = 4685), enrolled in the Provider Assessment of Lipid Management (PALM) registry and treated at 140 outpatient clinics across the United States in 2015. Patient self-estimated CV risk, patient-perceived statin benefit and risk, observed statin therapy use and dosing were assessed. RESULTS:Patients with DM were more likely to believe that their CV risk was elevated compared with patients without DM (39.1% vs 29.3%, P < .001). Patients with DM were more likely to receive a statin (74.2% vs 63.5%, P < .001) but less likely to be treated with guideline-recommended statin intensity (36.5% vs 46.9%, P < .001), driven by the low proportion (16.5%) of high risk (ASCVD risk ≥7.5%) primary prevention DMpatients treated with a high intensity statin. Patients with DM treated with guideline-recommended statin intensity were more likely to believe they were at high CV risk (44.9% vs 38.4%, P = .005) and that statins can reduce this risk (41.1% vs 35.6%, P = .02), compared with patients treated with lower than guideline-recommended statin intensity. Compared with patients with an elevated HgbA1c, patients with well-controlled DM were no more likely to be on a statin (77.9% vs 79.3%, P = .43). CONCLUSIONS: In this nationwide study, the majority of patients with DM were treated with lower than guideline-recommended statin intensity. Patient education and engagement may help providers improve lipid therapy for these high-risk patients.
Authors: Paul S Jellinger; Donald A Smith; Adi E Mehta; Om Ganda; Yehuda Handelsman; Helena W Rodbard; Mark D Shepherd; John A Seibel Journal: Endocr Pract Date: 2012 Mar-Apr Impact factor: 3.443
Authors: Yashashwi Pokharel; Kensey Gosch; Vijay Nambi; Paul S Chan; Mikhail Kosiborod; William J Oetgen; John A Spertus; Christie M Ballantyne; Laura A Petersen; Salim S Virani Journal: J Am Coll Cardiol Date: 2016-09-20 Impact factor: 24.094
Authors: Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah Journal: J Am Coll Cardiol Date: 2018-11-10 Impact factor: 24.094
Authors: Emelia J Benjamin; Salim S Virani; Clifton W Callaway; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Stephanie E Chiuve; Mary Cushman; Francesca N Delling; Rajat Deo; Sarah D de Ferranti; Jane F Ferguson; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Pamela L Lutsey; Jason S Mackey; David B Matchar; Kunihiro Matsushita; Michael E Mussolino; Khurram Nasir; Martin O'Flaherty; Latha P Palaniappan; Ambarish Pandey; Dilip K Pandey; Mathew J Reeves; Matthew D Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Uchechukwu K A Sampson; Gary M Satou; Svati H Shah; Nicole L Spartano; David L Tirschwell; Connie W Tsao; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2018-01-31 Impact factor: 29.690
Authors: Ann Marie Navar; Tracy Y Wang; Anne C Goldberg; Jennifer G Robinson; Veronique L Roger; Peter F Wilson; Salim S Virani; Joesph Elassal; L Veronica Lee; Laura E Webb; Eric Peterson Journal: Am Heart J Date: 2015-08-07 Impact factor: 4.749
Authors: Angela Lowenstern; Shuang Li; Ann Marie Navar; Salim Virani; L Veronica Lee; Michael J Louie; Eric D Peterson; Tracy Y Wang Journal: Am Heart J Date: 2018-03-24 Impact factor: 4.749
Authors: Angela Lowenstern; Ann Marie Navar; Shuang Li; Salim S Virani; Anne C Goldberg; Michael J Louie; L Veronica Lee; Eric D Peterson; Tracy Y Wang Journal: Am J Cardiol Date: 2019-01-04 Impact factor: 2.778
Authors: Nathan D Wong; Christopher Patao; Kalina Wong; Shaista Malik; Stanley S Franklin; Uchenna Iloeje Journal: Diab Vasc Dis Res Date: 2013-08-22 Impact factor: 3.291
Authors: C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins Journal: Lancet Date: 2010-11-08 Impact factor: 79.321
Authors: Sarah Stark Casagrande; Judith E Fradkin; Sharon H Saydah; Keith F Rust; Catherine C Cowie Journal: Diabetes Care Date: 2013-02-15 Impact factor: 19.112
Authors: Adam J Nelson; Kevin Haynes; Sonali Shambhu; Zubin Eapen; Mark J Cziraky; Michael G Nanna; Sara B Calvert; Kerrin Gallagher; Neha J Pagidipati; Christopher B Granger Journal: J Am Coll Cardiol Date: 2022-05-10 Impact factor: 27.203
Authors: Neal W Dickert; Andrea R Mitchell; Grace E Venechuk; Daniel D Matlock; Miranda A Moore; Alanna A Morris; Kenneth J Pierce; Candace D Speight; Larry A Allen Journal: Circ Cardiovasc Qual Outcomes Date: 2020-12-11